TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04078919

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nut consumption
Description: daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low calorie diet
Description: Low calorie diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: Low calorie diet
Study: NCT02881073

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maternal plasma PlGF quantification
Description: A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
Study: NCT00124449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: solution, intravenous injection, monthly, 169 days~weight based:~\<60 kg = 500 mg~60 to 100 kg = 750 mg~\>100 kg = 1 g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution, intravenous injection, 0 mg, monthly, 169 days
Study: NCT02589769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unsaturated fat for saturated fat
Description: Substituting unsaturated fat for saturated fat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saturated fat
Description: a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
Study: NCT04706871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the cymba conchae and concha around the left ear.
Study: NCT04706871

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tnVNS
Description: tnVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the antihelix around the left ear.
Study: NCT04651023

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nelumbo nucifera Leaf Extract
Description: Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
Study: NCT02957786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine tablets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural support
Description: Withdrawal-orientated cessation support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural support
Description: Withdrawal-orientated cessation support

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline tablets
Study: NCT03255031

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet (KD)
Description: For each meal at breakfast, lunch and dinner, the diets will consist of ketogenic diet (KD) meal. Compliance tests are done twice a week with a blood test measuring ketone levels.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard American (SA) Meals and Shakes
Description: For each meal at breakfast, lunch and dinner, the diets will consist of SA meal (carbohydrate rich) KD meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
Study: NCT02033876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Study: NCT02490566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
Study: NCT03667625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional Mobility Exercises
Description: Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional Mobility Exercises
Description: Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks
Study: NCT01596816

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: First part of treatment : Conformal irradiation
Description: 23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: First part of treatment : Conformal irradiation
Description: 23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiducials placement
Description: Placement of intra-prostatic markers for the tracking

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiducials placement
Description: Placement of intra-prostatic markers for the tracking
Study: NCT03594786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular aneurysm repair (EVAR)
Description: Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
Study: NCT06311448

Intervention type: DRUG
Intervention: Single target immunomodulation
Description: Single target immunomodulation compromise of drugs which very specifically target cytokines, chemokines or specific receptors, which are involved in the pathofysiology of COVID-19. For instance, tociluzimab (IL-6 receptor blocker), Anakinra (IL-1 receptor blocker), Eculizimab (Complement inhibitor C5), etc.

Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care during COVID-19 pandemic including steroids.
Study: NCT01596816

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Second part : hypofractionated stereotactic boost
Description: 3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Second part : hypofractionated stereotactic boost
Description: 3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
Study: NCT04455074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FN scale auto-questionnaire
Description: Patients will be asked to fill in the NF scale questionnaire together with other tests and rating scales, during a routine L-Dopa test, in 2 conditions: OFF-med and ON-med.
Study: NCT02140073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole+domperidone SR
Description: omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: 40mg in the morning
Study: NCT01652118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT03716505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore Sapphire active
Description: GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore Sapphire Sham
Description: The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.
Study: NCT04429373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant installation with PRF membrane
Description: Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant installation without PRF membrane
Description: Implant installation contralateral to the experimental side without PRF membrane
Study: NCT04651023

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nelumbo nucifera Leaf Extract
Description: Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nelumbo nucifera Leaf Extract
Description: Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
Study: NCT03943732

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray Pneumonia
Description: FilmArray Pneumonia testing of tracheal sample
Study: NCT01477034

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
Study: NCT02730039

Intervention type: BEHAVIORAL
Intervention: workshop

Intervention type: BEHAVIORAL
Intervention: follow-up calls & webinars

Intervention type: BEHAVIORAL
Intervention: assessments
Study: NCT01126593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
Study: NCT04624269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
Study: NCT03242382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
Study: NCT02460874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 1.25mg, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glyburide
Description: 1.25mg, twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.25mg, twice a day
Study: NCT03016663

Intervention type: PROCEDURE
Intervention: Technique of Breast Lipofilling
Description: 1. Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.~2. Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.~   Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).~3. Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.~4. Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided.
Study: NCT01873638

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cholecystectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cholecystectomy
Study: NCT01591031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
Study: NCT02191956

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Parent Training
Description: Weekly clinic session, mid-week call, home practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: Weekly clinic session, mid-week call, home practice
Study: NCT03151499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Reference and Test Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Test Treatment
Study: NCT00856778

Intervention type: DEVICE
Group type: OTHER
Intervention: Virtue® Male Incontinence Sling
Description: The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
Study: NCT00938600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 oral liquid 70,000 IU once

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 oral liquid 70,000 IU once

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
Study: NCT01956682

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HA formula + starch + L. reuteri
Study: NCT00615771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Day 3 embryo transfer
Description: Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Description: Embryos are transferred 1 day prior to standard of care
Study: NCT00971672

Intervention type: OTHER
Intervention: Questionnaire filling and laboratory analysis
Description: A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis.

Intervention type: OTHER
Intervention: Questionnaire filling and laboratory analysis
Description: A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis.
Study: NCT03671265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT or VMAT
Description: The IMRT or VMAT technique was used in our study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
Study: NCT04160949

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study: NCT03812068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long-distance developmental behavioral intervention
Description: Long-distance learning program combined parent-mediated developmental behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental behavioral intervention
Description: Parent-mediated developmental behavioral intervention
Study: NCT02371967

Intervention type: DRUG
Intervention: Vismodegib
Description: Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.

Intervention type: DRUG
Intervention: Vismodegib
Description: Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.

Intervention type: DRUG
Intervention: Vismodegib
Description: Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
Study: NCT00355069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic (computer based) provider feedback tool
Description: All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic (computer based) provider feedback tool
Description: All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic (computer based) provider feedback tool
Description: All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: electronic (computer based) provider feedback tool
Description: All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
Study: NCT00845754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: 15mg IV every6 hours for 4doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 15mg IV every 6hrs for 4 doses
Study: NCT03057119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-educational content (5 Minutes)
Description: The interventionist will discuss substance use and misuse and the influence of substance use on self care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Readiness Assessment (10 minutes)
Description: The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
Study: NCT00769899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: Capsule for oral, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule for oral, single dose
Study: NCT02115685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
Study: NCT01403454

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Health Communication Application
Description: web-based application
Study: NCT01605461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA
Description: Single oral solution dose of BI 207127 NA combined with \[14C\]-BI 207127 NA
Study: NCT01294878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
Study: NCT00446654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047
Description: 16.5 mg (3.3%) subconjunctival injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047
Description: 16.5 mg (3.3%) subconjunctival injection